Corvus Pharmaceuticals, Inc. (CRVS)
| Market Cap | 1.25B +450.3% |
| Revenue (ttm) | n/a |
| Net Income | -15.28M |
| EPS | -0.53 |
| Shares Out | 84.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 704,370 |
| Open | 15.47 |
| Previous Close | 15.45 |
| Day's Range | 14.60 - 15.59 |
| 52-Week Range | 3.17 - 26.95 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 30.17 (+103.17%) |
| Earnings Date | May 7, 2026 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CRVS stock is "Strong Buy." The 12-month stock price target is $30.17, which is an increase of 103.17% from the latest price.
News
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.
SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D...
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
Two oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free re...
Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Corvus Pharmaceuticals (CRVS) with a Buy rating and $40 price target The shares trade at an attractive entry point given the company’s “leading emerging” oral
Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer
Oppenheimer raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $33 from $32 and keeps an Outperform rating on the shares after the company reported full year 2025 results
Corvus Pharmaceuticals files automatic mixed securities shelf
08:03 EDT Corvus Pharmaceuticals (CRVS) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the t...
Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025
Soquelitinib showed strong efficacy and durable responses in atopic dermatitis and PTCL, with robust safety and broad applicability. Financial position is solid after a $200M financing, supporting an expanded clinical pipeline and cash runway into 2028.
Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)
“We believe the recent cohort 4 data from our Phase 1 atopic dermatitis trial demonstrate that soquelitinib has the potential to be an important new medicine for a broad range
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy
Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings
Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 7.9%, or $1.28, after results ar...
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings
Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is normal with calls leading puts 8:1. Implied volatility suggests the market is anticipating a move near 5.5%, or 99c, after results are
Corvus Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Soquelitinib, a selective oral ITK inhibitor, demonstrated strong efficacy and durable responses in atopic dermatitis, including in patients resistant to prior therapies, with a favorable safety profile. Large market opportunities exist, and multiple phase II and III trials are planned through 2026.
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership t...
Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $30 from $20 and keeps an Outperform rating on the shares. The firm cites a “meaningful
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underw...
Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies
Jefferies analyst Roger Song raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $42 from $13 and keeps a Buy rating on the shares. The firm views the Phase
Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15
The deal size was increased to $175M in common stock from $150M in common stock. Jefferies and Goldman Sachs acted as joint book running managers for the offering. Published first
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underw...
Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer
Oppenheimer raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $32 from $15 and keeps an Outperform rating on the shares after the company announced additional atopic dermatitis data
Corvus Pharmaceuticals announces $150M common stock offering
Corvus Pharmaceuticals (CRVS) announced that it has commenced an underwritten public offering of $150M of shares of its common stock and, in lieu of common stock to certain investors, pre-funded
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwr...
Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays
Barclays raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $28 from $16 and keeps an Overweight rating on the shares after the company reported positive Phase 1 data
What made Corvus stock double on Tuesday and is it sustainable?
Corvus Pharmaceuticals (NASDAQ: CRVS) shares more than doubled on Jan. 20 after announcing positive Phase 1 trial data for “soquelitinib” – its oral investigational drug for atopic dermatitis. Soqueli...
Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho
Mizuho raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $20 from $13 and keeps an Outperform rating on the shares. The company reported positive Phase 1 data for
Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright
H.C. Wainwright analyst Sean Lee raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $27 from $11 and keeps a Buy rating on the shares after the company announced